Cardiac fibroblasts account for about 75% of all cardiac cells, but because of their small size contribute only 10 -15% of total cardiac cell volume. They play a crucial role in cardiac pathophysiology. For a long time, it has been recognized that fibroblasts and related cell types are the principal sources of extracellular matrix (ECM) proteins, which organize cardiac cellular architecture. In disease states, fibroblast production of increased quantities of ECM proteins leads to tissue fibrosis, which can impair both mechanical and electrical function of the heart, contributing to heart failure and arrhythmogenesis. Atrial fibrosis is known to play a particularly important role in atrial fibrillation (AF). This review article focuses on recent advances in understanding the molecular electrophysiology of cardiac fibroblasts. Cardiac fibroblasts express a variety of ion channels, in particular voltage-gated K + channels and non-selective cation channels of the transient receptor potential (TRP) family. Both K + and TRP channels are important determinants of fibroblast function, with TRP channels acting as Ca 2+ -entry pathways that stimulate fibroblast differentiation into secretory myofibroblast phenotypes producing ECM proteins. Fibroblasts can couple to cardiomyocytes and substantially affect their cellular electrical properties, including conduction, resting potential, repolarization, and excitability. Co-cultured preparations of cardiomyocytes and fibroblasts generate arrhythmias by a variety of mechanisms, including spontaneous impulse formation and rotor-driven reentry. In addition, the excess ECM proteins produced by fibroblasts can interrupt cardiomyocyte-bundle continuity, leading to local conduction disturbances and reentrant arrhythmias. A better understanding of the electrical properties of fibroblasts should lead to an improved comprehension of AF pathophysiology and a variety of novel targets for antiarrhythmic intervention.
Introduction
Cardiac fibrosis is a pathological response that causes abnormalities in cardiac conduction and mechanical function, thereby contributing to the pathophysiology of a variety of cardiac conditions, including hypertrophy, failure, and arrhythmias. 1 Atrial fibrillation (AF) is the most common sustained clinical arrhythmia and is a major cause of population morbidity and mortality. 2 Recent studies have demonstrated that structural remodelling, involving prominent fibrotic changes, is a fundamental determinant of the perpetuation of AF, and contributes synergistically with electrical remodelling to the AF substrate. 3, 4 Atrial fibrosis is a hallmark feature of arrhythmogenic structural remodelling in clinical AF. 5 Increased amounts of fibrous tissue occur not only in AF patients with identifiable cardiac diseases, 6, 7 but also in those with lone AF. 6, 8 There is a positive correlation between the amount of fibrosis and the persistence of AF, 7 suggesting that AF may itself cause structural remodelling that in turn promotes AF. Evidence supporting this idea comes from animal studies showing that even when the ventricular rate is well-controlled, rapid atrial activation causes atrial fibrosis, 9 and from work indicating that rapidly activated atrial-derived cardiomyocytes secrete substances that enhance collagen synthesis by atrial fibroblasts. 10 Fibrosis represents excessive deposition of extracellular matrix (ECM) proteins synthesized by fibroblast-related cells, particularly myofibroblasts, upon stimulation. 11 Fibroblasts are the most abundant cell type by number in the myocardium, about 75% of all cells. 12 Because of their small size, they comprise 5-10% of the total mammalian heart volume, 13 but up to 75% of sinoatrial node (SAN)
volume. 14 In contrast to cardiomyocytes, 15 cardiac fibroblasts are electrically non-excitable, 16 and were initially thought to serve a predominantly structural role. 17, 18 Over the past 10 years, however, a growing body of evidence suggests that cardiac fibroblasts importantly modify cardiac electrical function. Myofibroblasts are rarely found in normal cardiac tissue. 19 In response to pathological stimuli, such as myocardial injury, oxidative stress, mechanical stretch, enhanced autocrine-paracrine mediator production, and inflammatory stimuli, fibroblasts proliferate, migrate, and undergo phenotypic changes involving differentiation into myofibroblasts, 20, 21 which are the principal ECM-secretory cell type. Myofibroblasts may also be derived from cardiac endothelial cells 22 and from circulating precursors. 23 By producing growth factors, cytokines, chemokines, ECM proteins, and proteases, 24, 25 myofibroblasts play a pivotal role in the fibrotic process. Cytokines and other growth factors produced by myofibroblasts can further stimulate fibroblasts, perpetuating a fibrogenic cascade. Fibroblasts produce two types of fibrosis, reactive and reparative. 4, 26 Reparative fibrosis fills in tissue and maintains structural integrity after cardiomyocyte death, whereas reactive fibrosis is a response to excessive myocardial loads or inflammation and causes ECM expansion between muscle bundles 4 ( Figure 1 ). The goal of this paper is to review recent developments in understanding the pathophysiology of cardiac fibroblasts and their role in AF development and perpetuation, with a particular focus on the properties of fibroblasts relevant to cardiac and more specifically atrial electrical function.
Differences between atrial and ventricular fibroblasts
A number of observations suggest that the atria are more susceptible to fibrosis than the ventricles. 27 -31 While various mechanisms, including differential stretch and mechanical-loading properties, may contribute to the atrial fibrotic susceptibility, there is evidence that there are fundamental differences between atrial and ventricular fibroblasts. 32 In culture, atrial fibroblasts show faster increases in cellsurface area typical of myofibroblast differentiation and a distinct morphology at confluence. 32 Atrial fibroblasts also show proliferative responses that are greater than those of ventricular fibroblasts upon exposure to a range of growth stimuli, including foetalbovine serum, platelet-derived growth factor (PDGF), basic fibroblast growth factor, angiotensin II (AngII), endothelin-1, and transforming growth factor (TGF)-b1. 32 Atrial fibroblasts express PDGF and Figure 1 Schematic diagram of cardiac fibrogenesis cascade and AF. In response to a variety of stimuli, cardiac fibroblasts proliferate, differentiate, synthesize extracellular matrix (ECM) proteins, and produce cytokines that in turn stimulate fibroblasts, thereby providing positive feedback and perpetuating the fibrogenesis cascade. ECM accumulation causes fibrosis that favours the occurrence and maintenance of AF. There are two types of fibrosis, reactive and reparative, which can be caused by many common stimuli, with cardiomyocyte death required for reparative fibrosis. TRPM7-mediated Ca 2+ signals are critical for fibroblast proliferation, differentiation, and ECM production in fibroblasts from AF patients. 67 Fibroblast Ca 2+ signalling may be an effective target for the prevention of fibrogenesis.
Fibroblasts in cardiac bioelectricity and AF PDGF-receptor mRNA more strongly than ventricular fibroblasts, congestive heart failure (CHF) differentially enhances atrial vs. ventricular PDGF and PDGF-receptor gene expression, and PDGF-receptor inhibition suppresses atrial-specific responses, pointing to a role for PDGF in atrial-selective fibrosis. 32 
Electrophysiological properties of cardiac fibroblasts
The resting membrane potential (RMP) of cardiac fibroblasts is much less negative than that of cardiomyocytes. RMP in fibroblasts can be measured by whole-cell patch clamp (under current clamp mode), with limitations of altering cell contents by dialysis and the need for junction potential compensation, or by classical fine-tipped microelectrodes, which is technically challenging and can cause mechanical cell damage. Values between 231 and 216 mV have been recorded in situ with standard sharp microelectrodes in atrial fibroblasts, 33, 34 vs. 270 to 280 mV for atrial cardiomyocytes. Patch clamp recordings in isolated rat atrial fibroblasts indicate a RMP of about 237 mV. 35 The fibroblast RMP becomes hyperpolarized during atrial relaxation and depolarized during atrial contraction, 35 presumably due to activation and inactivation of a mechanosensitive non-selective cation channel.
35 41 It will be important to determine whether and how the various ion channels in fibroblasts contribute to basic fibroblast function, as well as to fibroblast-cardiomyocyte interactions. 48 In an in vivo study, mibefradil, a mixed L/T-type Ca 2+ -channel blocker, reduced collagen production and fibroblast differentiation in rats receiving AngII or aldosterone. 49 These studies suggest has only one member, TRPA1. The TRPP (polycystin) and TRPML (mucolipin) families, each with three members, are likely intracellular ion channels. 53 TRP channels consist of putative six transmembrane polypeptide subunits assembling as homo-or hetero-tetramers to form cationpermeable pores. TRP channels have few charged amino acids in the S4 domain, making them only weakly voltage responsive. 50, 51 Some TRP channels are constitutively open, others open upon Gq-linked receptor activation. 50 -52 All functionally characterized TRP channels are permeable to Ca 2+ except TRPM4 and TRPM5.
Ca 21 signalling and fibroblast function
TRPM6 and TRPM7 are also permeable to Mg 2+ .
TRP channels in the heart
TRP channels are highly expressed in heart. 54 Aortic banding upregulates TRPC1 55 current was evident at whole-cell and single-channel levels, whereas TRPC6-, TRPV2-, and TRPV4-like currents were not elicited.
67
A non-selective cation current (NSCC) was elicited by CNP (C-type natriuretic peptide) and cANP in freshly isolated rat ventricular fibroblasts. 68 NSCC can also be activated by OAG (1-oleoyl-2-acety-sn-glycerol), suggesting that TRPC3, TRPC6, or TRPC3/TRPC6 heteromers may underlie NSCC in rat ventricular fibroblasts. 68 Fibroblasts in cardiac bioelectricity and AF
How do fibroblasts affect cardiac electrical function?
Cardiac fibrosis plays a central role in the pathophysiology of AF. 4 Myofibroblast content increases are clearly involved in the fibrotic process. CHF enhances myofibroblast content in the atria much more than in the ventricles, a phenomenon clearly related to the atrial selectivity of fibrotic processes and their role in AF. 32 The precise mechanisms by which fibrosis promotes AF are a subject of active interest, and particular attention has been paid to the involvement of atrial fibroblasts in atrial electrical dysfunction and arrhythmogenesis.
Cardiomyocyte -fibroblast electrical interactions and arrhythmogenesis
Fibroblast coupling to cardiomyocytes can produce a variety of changes in cardiomyocyte action potential (AP) properties, 15,73 -77 including changes in pace-making function. 15, 78 Fibroblasts are capable of coupling electrically to cardiomyocytes. 79 The complement of fibroblast ion channels produces a moderately polarized (negative intracellular) potential (about 230 mV), without active depolarization properties mediated by voltage-gated Na + or Ca 2+ channels. Fibroblasts modulate cardiomyocyte electrical activity by depolarizing or hyperpolarizing cardiomyocytes depending on the relative values of cardiomyocyte vs. fibroblast transmembrane potential. Lacking active phase 0 depolarization, fibroblast cell membranes possess a capacitance in parallel to their resistance, making them leaky capacitors. They also display a variety of ion channels that show voltageand time-dependent conductance. 73 When cardiomyocytes are depolarized to voltages positive to about 230 mV (the normal fibroblast resting potential), the gap-junctional flow of positive ions towards the more negatively charged fibroblast produces repolarizing cardiomyocyte current flow that can mimic transient outward current. 76 Conversely, when the cardiomyocyte transmembrane potential is negative to 230 mV, positively charged gap-junctional current flow from fibroblasts will depolarize cardiomyocytes. As a result, cardiomyocyte -fibroblast coupling depolarizes cardiomyocyte RMP, slows conduction by drawing off excitatory current flow during phase 0, and can increase or decrease AP duration (APD) depending on fibroblast resting potential and cardiomyocyte-fibroblast coupling properties.
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Figure 2 schematically illustrates the effects of coupled fibroblasts on cardiomyocyte electrical activity. Figure 2A shows recordings of fibroblast and cardiomyocyte transmembrane potential as they would look if the cell types were not electrically coupled, with a typical cardiomyocyte AP and the fibroblast at a constant transmembrane potential determined by its intrinsic ionic permeabilities. Figure 2B shows the effects of coupling the cell types. Whenever the cardiomyocyte membrane potential is different from 230 mV, current flows through gap junctions between the cells (as well as in the extracellular fluid around them, as indicated in the figure), depolarizing cardiomyocytes and hyperpolarizing fibroblasts when the cardiomyocyte potential is negative to 230 mV, and conversely hyperpolarizing cardiomyocytes and depolarizing fibroblasts when the cardiomyocyte potential is positive to 230 mV. Prior to activation, during phase 4 when the cardiomyocyte is normally at rest (Figure 2Ba) , current flow from fibroblasts depolarizes the cardiomyocyte cell membrane. Theoretically, this could initiate spontaneous phase 0 depolarization and automaticity if the cardiomyocyte reaches threshold potential. Phase 0 depolarization in cardiomyocytes is slowed because the phase 4 depolarization resulting from coupling to fibroblasts inactivates cardiomyocyte Na + channels. In addition, when the cardiomyocyte potential is positive to 230 mV, cardiomyocytes experience an outward (hyperpolarizing) current flow to fibroblasts which oppose the effect of inward Na + current (Figure 2Bb ).
Throughout phases 1 and 2, this outward cardiomyocyte current flow continues and accelerates repolarization. Phase 3 is initially accelerated, but when the cardiomyocyte returns to 230 mV the direction of current flow is reversed and the cardiomyocyte is now depolarized by the attached fibroblast, slowing repolarization. Current flow across the fibroblast cell membrane is inversely parallel to that in the cardiomyocyte, producing changes in fibroblast transmembrane potential that are qualitatively similar to, but smaller than, those in the cardiomyocyte. Net effects on cardiomyocyte APD will depend on whether initial repolarization accelerating effects (positive to the fibroblast intrinsic potential) predominate, shortening APD, or whether terminal repolarization delaying effects (negative to fibroblast intrinsic potential) predominate, increasing APD. Conduction will be slowed, because of the reduced phase 0 slope. In pathological conditions, intervening fibroblasts can actually couple otherwise-uncoupled cardiomyocytes, producing extremely slow conduction that can greatly facilitate the occurrence of reentry. 80 The effects of fibroblasts on cardiomyocyte electrical activity will clearly depend on a variety of factors. Based on the cellular actions shown in Figure 2 , one would expect fibroblasts to be able to induce both abnormal spontaneous impulse formation (abnormally enhanced automaticity) and reentry in cardiac tissues. Abnormal automatic activity is induced by depolarization of cardiomyocytes towards their threshold potential, as well as by the induction of voltage-and time-dependent inward Na + and/or Ca 2+ currents at depolarized potentials. Reentry results from conduction slowing and APD abbreviation in cardiomyocytes. Both abnormal automaticity and reentry have been shown to occur in co-cultures of cardiomyocytes and fibroblasts. 81, 82 Based on modelling predictions, factors that determine the ability of fibroblasts to modulate cardiomyocyte electrical activity include the number of resident fibroblasts in any given cardiac region and the effectiveness of their coupling to cardiomyocytes. 73 -77 Fibroblasts are small cells. Although they are numerous in the heart, their much smaller size means that many fibroblasts need to be coupled to cardiomyocytes to affect their electrical activity-significant effects are observed with 10 -30 fibroblasts per cardiomyocyte in computer modelling. 15, 75, 83 This result needs to be considered cautiously, because size estimates may be inaccurate if, as some believe, cell isolation damages fibroblasts so that they are isolated as nucleated fragments rather than intact cells. The in vivo contexts in which fibroblast coupling significantly modulates cardiomyocyte electrical activity remain unknown, although the large numbers of fibroblasts in the SA node suggest that they may be particularly important in regulating SA node pacemaker activity. 14, 79 Similarly, the degree, types, and effectiveness of cardiomyocyte -fibroblast coupling in various pathological contexts is uncertain, although it is known that fibroblasts expressing connexins 40 and 43 appear in large numbers in evolving myocardial infarctions. 84 There is a paucity of data about cardiomyocyte -fibroblast gap-junction coupling from in situ preparations, whereas in vitro data indicate extensive formation of Cx43-and Cx45-based inter-myofibroblast and myofibroblast-cardiomyocyte coupling. 80 A mathematical model incorporating fibroblast-cardiomyocyte interactions accounted well for the effects of tissue fibrosis on electrical propagation during AF in sheep with CHF induced by chronic rapid ventricular pacing. 85 An interesting recent finding has been that cardiac fibroblasts can Fibroblasts in cardiac bioelectricity and AF produce paracrine factors that affect cardiac electrical activity. 86 Neonatal-rat cardiomyocyte monolayers exposed for 24 h to conditioned media from cardiac fibroblasts showed significant conduction-slowing, APD prolongation and reduced follow frequency. It is therefore possible that cardiomyocyte electrical activity is affected by diffusible factors from adjacent fibroblasts in fibrotic tissues. Overall, while it is clear from studies in model systems that fibroblast-cardiomyocyte interactions can produce AF-promoting electrophysiological changes, the extent to which they contribute to clinical arrhythmias like AF is at present still an unresolved issue of great interest.
'Barrier' function of fibrotic tissue and altered cardiac electrical continuity
Another way in which fibroblasts can promote arrhythmogenesis is by producing large quantities of ECM proteins, particularly collagen, that alter cardiomyocyte architecture and disturb electrical continuity. Tissue fibrosis in AF develops in parallel with local conduction disturbances and increases in AF persistence, during both the development and resolution of experimental CHF, in contrast to a variety of other CHF-related changes. 87, 88 ECM alterations in fibrotic tissue could lead to conduction abnormalities and AF promotion in a variety of ways. Loss of side-to-side cardiomyocyte connections due to insulating collagen within cardiomyocyte bundles has been suggested to produce zigzag conduction patterns and promote atrial microreentry with ageing. 89 The potential effects of fibrosis on longitudinal conduction, the dominant conduction form in highly anisotropic atrial tissue, 90, 91 are illustrated in Figure 3 . The normal architecture of cardiomyocyte bundles is shown schematically in Figure 3A . Figure 3B illustrates the effects of reactive fibrosis, which increases the collagen content in the interstitial spaces between fibres. 4 Fibrosis occurs around cardiomyocyte bundles. Longitudinal conduction is uninterrupted, and could even be accelerated due to better insulation of cable-like bundles. Figure 3C illustrates the effect of reparative fibrosis, in which dead cardiomyocytes are replaced by fibrous tissue, 4 which then physically separates cardiomyocytes in the longitudinal direction and interferes with longitudinal conduction. Experimental observations in a canine CHF model are shown in Figure 4A , and indicate that both during CHF and following full recovery from CHF fibrotic tissue interrupts cardiomyocyte-bundle continuity in the longitudinal direction. 88 Optical mapping shows conduction abnormalities in atrial tissues of dogs recovered from CHF ( Figure 4B ). A mathematical model assuming that fibrous tissue impairs atrial conduction by physically interrupting cardiomyocyte muscle-bundle connections fully accounts for CHF-related conduction abnormalities ( Figure 4C ). 88 Furthermore, AF promotion tracked both conduction abnormalities and fibrosis in this CHF model, arguing for an important role of fibrotic conduction barriers in AF maintenance. 88 These results support the notion that fibrosis impairs conduction by acting as a barrier to continuous longitudinal conduction in cardiomyocyte bundles. It has been suggested that the maintenance of transmural conduction in chronically infarcted regions of rabbit hearts may be due to cardiomyocyte -fibroblast coupling in scarred myocardium. 92 An interesting recent tissue-engineering study showed that inserting a layer of fibroblast-derived NIH3T3 cells between two sheets of neonatal rat cardiomyocytes restores electrical conduction between the cardiomyocyte sheets, suggesting the time-dependent development of electrical coupling across the fibroblast sheet. 93 
Therapeutic implications
Given the important role of atrial fibrosis in AF pathophysiology, therapeutic approaches that target fibroblast function are potentially of interest. Angiotensin converting-enzyme inhibitors, which suppress renin-angiotensin-aldosterone system (RAAS) activation, were the first agents shown experimentally to suppress atrial fibrosis, prevent atrial conduction abnormalities, and attenuate associated AF promotion. 94 Subsequent experimental evidence indicated similar effects from angiotensin type-1 receptor antagonists 95 and aldosterone inhibitors. 96 Statins suppress atrial fibroblast proliferation and suppress atrial fibrosis/AF in experimental CHF 97 and omega-3 fatty acids have similar antifibrotic/AF-suppressing actions, 98 possibly via anti-inflammatory/antioxidant actions. Pirfenidone, an antifibrotic drug that appears to act by interfering with TGF-b signalling, also suppresses fibrosis, conduction abnormalities, and AF promotion resulting from CHF. 99 Heat-shock protein inducers like geranylgeranylacetone also attenuate atrial remodelling and CHF-related fibrosis. 100, 101 Clinical data are still insufficient to draw definite conclusions, but support the concept that RAAS inhibition can prevent AF, at least in some patient populations.
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The electrical properties of fibroblasts also open up exciting and novel therapeutic possibilities. If Ca 2+ entry through TRP channels plays a central role in fibroblast activation, as suggested by experimental data, 67, 104 then TRP channel blockers have the potential to be useful AF-preventing drugs. The prevention of fibroblast-cardiomyocyte interactions, by targeting fibroblast ion channels or fibroblastcardiomyocyte coupling, offers additional novel and exciting possibilities in AF therapy. For example, if fibroblast coupling to cardiomyocytes causes atrial ectopic activity or reentry that underlies AF occurrence, specifically targeting cardiomyocyte-fibroblast coupling mechanisms could suppress AF. There may be ways of stopping fibroblast-induced abnormal automaticity or reentry by developing drugs that selectively inhibit or activate fibroblast ion channels. We are only beginning to understand the detailed function and pathophysiology of atrial fibroblasts and how they contribute to AF development, but the new insights and therapeutic possibilities that they present are exciting.
Conclusions
Fibroblasts are quantitatively and qualitatively a very important cell type in the heart. Extensive evidence suggests that tissue fibrosis, involving proliferation of fibroblasts and increased fibroblast-derived ECM protein expression, plays an important role in AF. Rapidly accumulating information suggests that the electrical properties of cardiac fibroblasts are important in governing both their ECM protein-producing properties and arrhythmogenic events related to cardiomyocyte -fibroblast interaction. Work in this exciting field promises to lead to new mechanistic insights and therapeutic options for AF.
